Axsome Therapeutics (AXSM) Other Operating Expenses (2020 - 2026)

Axsome Therapeutics (AXSM) has 6 years of Other Operating Expenses data on file, last reported at $16.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 31.18% year-over-year to $16.9 million; the trailing twelve-month figure through Mar 2026 stood at $101.6 million (up 36.87% YoY), and the FY2025 full-year result was $51.4 million, down 24.24% from the prior year.
• Other Operating Expenses slipped to $16.9 million in Q1 2026, from $51.1 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $52.2 million in Q4 2023 to a low of $1.0 million in Q2 2022.
• A 5-year average of $17.3 million and a median of $12.0 million in 2023 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses soared 1066.92% in 2023 and slumped 55.73% in 2024, its largest moves.
• Tracing AXSM's Other Operating Expenses over 5 years: stood at $8.1 million in 2022, then surged by 544.5% to $52.2 million in 2023, then tumbled by 55.73% to $23.1 million in 2024, then jumped by 120.98% to $51.1 million in 2025, then tumbled by 66.93% to $16.9 million in 2026.
• Business Quant data shows AXSM's Other Operating Expenses at $16.9 million in Q1 2026, $51.1 million in Q4 2025, and $26.7 million in Q3 2025.